Biodesix partners with Vanderbilt to develop AI-enabled lung nodule diagnostics combining imaging and blood biomarkers
Biodesix is collaborating with Vanderbilt University and Vanderbilt Health to develop an AI-enabled lung nodule risk assessment test combining imaging and blood-based biomarkers.
The programme will use radiomics-based imaging analysis alongside Biodesix's existing Nodify Lung blood diagnostics portfolio to investigate a multimodal approach to evaluating lung nodules.
Initial research data are scheduled for presentation in December 2026, with potential commercial availability anticipated in 2028, although the new diagnostic test remains under development and has not received regulatory clearance.
Field | Content |
Article Type | Deals |
Companies | Biodesix; Vanderbilt University; Vanderbilt Health |
Deal Type | Diagnostics research and development collaboration |
Therapeutic Area | Pulmonology; lung cancer diagnostics |
Development Focus | AI-enabled lung nodule risk assessment |
Technology | Radiomics-based imaging analysis combined with blood biomarkers |
Diagnostic Modality | Multimodal diagnostic testing |
Existing Product Portfolio | Biodesix Nodify Lung blood-based diagnostics |
Research Objective | Develop a lung nodule risk assessment test integrating imaging and blood-based biomarkers |
AI Application | Analysis of imaging-derived biomarkers to support risk assessment |
Development Stage | Research and development |
Regulatory Status | Investigational diagnostic; no new regulatory clearance reported |
Initial Data Presentation | Scheduled for 3 December 2026 |
Anticipated Commercial Availability | 2028; subject to development progress |
Financial Terms | Not disclosed in supplied summary |
Geography | United States |
What Happened | Biodesix announced a development collaboration with Vanderbilt University and Vanderbilt Health for an AI-enabled lung nodule diagnostic test. |
Why It Matters | Combining imaging and blood-based biomarkers could support more comprehensive assessment of lung nodules and help inform clinical decision-making if validated. |
Strategic Rationale | Biodesix aims to expand its diagnostics pipeline beyond blood-based tests by integrating radiomics and AI capabilities. |
Potential Impact | The programme could create a new multimodal diagnostic option for lung nodule evaluation following successful validation and any required regulatory processes. |
Key Takeaway | Biodesix is developing an AI-enabled lung nodule test with Vanderbilt; the product remains investigational and is not yet commercially available. |
What to Watch | Initial data presentation on 3 December 2026, validation results, regulatory plans and progress toward the anticipated 2028 commercial timeline. |
Primary Source | Biodesix |
Primary Source URL | https://biodesix.gcs-web.com/news-releases/news-release-details/biodesix-adds-digital-diagnostics-lung-pipeline-creating-new |
Relevant Date | 19 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios